Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 217
Inquire Before Buying

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016', provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas

- The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects

- The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Adenocarcinoma of The Pancreas Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview 11
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis 12
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies 13
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes 15
Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies 19
Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes 21
Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development 22
AbbVie Inc 22
Aduro BioTech, Inc. 23
Array BioPharma Inc. 24
Axcentua Pharmaceuticals AB 25
Berg LLC 26
Boehringer Ingelheim GmbH 27
Boston Biomedical, Inc. 28
CTI BioPharma Corp. 29
CytRx Corporation 30
Daiichi Sankyo Company, Limited 31
Eleison Pharmaceuticals LLC 32
Gilead Sciences, Inc. 33
GlaxoSmithKline Plc 34
Incyte Corporation 35
MabVax Therapeutics Holdings, Inc. 36
Merrimack Pharmaceuticals, Inc. 37
NewLink Genetics Corporation 38
Novartis AG 39
Oncolytics Biotech Inc. 40
Pfizer Inc. 41
Phoenix Biotechnology, Inc. 42
Targovax ASA 43
Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
(curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
aldoxorubicin hydrochloride - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
AXP-10711 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
BI-853520 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
binimetinib - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Cellular Immunotherapy for Oncology - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Cellular Immunotherapy for Oncology - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
ceritinib - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
glufosfamide - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
GS-5745 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
GSK-2256098 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
HuMab-5B1 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
ibrutinib - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
INCB-52793 - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
indoximod - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
irinotecan hydrochloride - Drug Profile 131
Product Description 131
Mechanism Of Action 131
R&D Progress 131
MesoCART - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 143
Product Description 143
Mechanism Of Action 143
R&D Progress 143
napabucasin - Drug Profile 145
Product Description 145
Mechanism Of Action 145
R&D Progress 145
nimotuzumab - Drug Profile 151
Product Description 151
Mechanism Of Action 151
R&D Progress 151
palbociclib - Drug Profile 155
Product Description 155
Mechanism Of Action 155
R&D Progress 155
PBI-05204 - Drug Profile 165
Product Description 165
Mechanism Of Action 165
R&D Progress 165
pelareorep - Drug Profile 167
Product Description 167
Mechanism Of Action 167
R&D Progress 167
PLX-7486 - Drug Profile 181
Product Description 181
Mechanism Of Action 181
R&D Progress 181
PRI-724 - Drug Profile 182
Product Description 182
Mechanism Of Action 182
R&D Progress 182
ribociclib succinate - Drug Profile 184
Product Description 184
Mechanism Of Action 184
R&D Progress 184
SGT-53 - Drug Profile 188
Product Description 188
Mechanism Of Action 188
R&D Progress 188
sonidegib phosphate - Drug Profile 190
Product Description 190
Mechanism Of Action 190
R&D Progress 190
TG-01 - Drug Profile 195
Product Description 195
Mechanism Of Action 195
R&D Progress 195
tosedostat - Drug Profile 198
Product Description 198
Mechanism Of Action 198
R&D Progress 198
ubidecarenone - Drug Profile 203
Product Description 203
Mechanism Of Action 203
R&D Progress 203
ulixertinib - Drug Profile 206
Product Description 206
Mechanism Of Action 206
R&D Progress 206
Vaccine for Oncology - Drug Profile 207
Product Description 207
Mechanism Of Action 207
R&D Progress 207
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects 208
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products 209
Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones 210
Featured News & Press Releases 210
Aug 04, 2016: Merrimack Provides Update on ONIVYDE 210
Jul 21, 2016: Baxalta receives CHMP positive opinion on Onivyde for the treatment of metastatic adenocarcinoma of the pancreas 210
Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer 211
May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 211
Apr 14, 2016: Targovax reports immune response with reduced number of TG01 vaccinations 212
Jan 25, 2016: Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium 212
Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission 214
Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer 215
Appendix 216
Methodology 216
Coverage 216
Secondary Research 216
Primary Research 216
Expert Panel Validation 216
Contact Us 216
Disclaimer 217

List of Tables
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016 11
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Metastatic Adenocarcinoma of The Pancreas - Pipeline by AbbVie Inc, H2 2016 22
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H2 2016 23
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H2 2016 24
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H2 2016 25
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Berg LLC, H2 2016 26
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H2 2016 27
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H2 2016 28
Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H2 2016 29
Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H2 2016 30
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 31
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals LLC, H2 2016 32
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H2 2016 33
Metastatic Adenocarcinoma of The Pancreas - Pipeline by GlaxoSmithKline Plc, H2 2016 34
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H2 2016 35
Metastatic Adenocarcinoma of The Pancreas - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016 36
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 37
Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H2 2016 38
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H2 2016 39
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H2 2016 40
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H2 2016 41
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H2 2016 42
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax ASA, H2 2016 43
Assessment by Monotherapy Products, H2 2016 44
Assessment by Combination Products, H2 2016 45
Number of Products by Stage and Target, H2 2016 47
Number of Products by Stage and Mechanism of Action, H2 2016 50
Number of Products by Stage and Route of Administration, H2 2016 53
Number of Products by Stage and Molecule Type, H2 2016 55
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H2 2016 208
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H2 2016 209

List of Figures
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016 11
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Assessment by Monotherapy Products, H2 2016 44
Number of Products by Top 10 Targets, H2 2016 46
Number of Products by Stage and Top 10 Targets, H2 2016 46
Number of Products by Top 10 Mechanism of Actions, H2 2016 49
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 49
Number of Products by Routes of Administration, H2 2016 52
Number of Products by Stage and Routes of Administration, H2 2016 52
Number of Products by Molecule Types, H2 2016 54
Number of Products by Stage and Molecule Types, H2 2016 54
  • United States Non-small Cell Lung Cancer Therapeutics Market Report 2016
    Published: 01-Dec-2016        Price: US 3800 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Non-small Cell Lung Cancer Therapeutics Revenue, means the sales value of Non-small Cell Lung Cancer Therapeutics This report studies sales (consumption) of Non-small Cell Lung Cancer Therapeutics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Onco......
  • Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 477
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfo......
  • Small-Cell Lung Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 588
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2016, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spr......
  • Gallbladder Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 74
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts......
  • Vaginal Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2016, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment include......
  • Epithelial Ovarian Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 507
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Epithelial Ovarian Cancer (Oncology) pipeline landscape.Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, p......
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 463
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline landscape.Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resis......
  • Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 108
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsen......
  • Follicular Lymphoma - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 540
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Follicular Lymphoma - Pipeline Review, H2 2016, provides an overview of the Follicular Lymphoma (Oncology) pipeline landscape.Follicular lymphoma is a common type of non-Hodgkin Lymphoma (NHL). It is a slow-growing lymphoma that arises from B-cells, a type of white blood cell. It is also called an "indolent" or "low-grade" lymphoma for its slow nature. Follicular lymphoma mainly affects older adults. Enlargeme......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs